Media
Press Releases
November 5, 2025
Lupin Receives EIR from U.S. FDA for its Pithampur Unit-3 Facility
October 28, 2025
Governor Murphy and Local Leaders Attend Ribbon-Cutting Ceremony, Marking the Inauguration of Lupin’s New Corporate Offices in Bridgewater
October 24, 2025
Lupin Launches Authorized Generic Version of Ravicti® in the United States
October 13, 2025
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
October 3, 2025
Lupin Launches Liraglutide Injection in the United States
October 1, 2025
Lupin Launches Rivaroxaban for Oral Suspension in the United States
September 30, 2025
Lupin Receives Approval from U.S. FDA for Rivaroxaban for Oral Suspension
September 24, 2025
Lupin Receives Tentative Approval from U.S. FDA for Bictegravir, Emtricitabine, and Tenofovir Alafenamide Tablets
September 17, 2025
Lupin Receives Approval from U.S. FDA for Lenalidomide Capsules
Media
Rajalakshmi Azariah
Vice President & Global Head - Corporate Communications
rajalakshmiazariah@lupin.comElise Titan
Director, U.S. Communications
elisetitan@lupin.comSmart Guide
Close
CloseSearch Product
Global Privacy Control Detected
We have detected your Global Privacy Control (GPC) signal. In accordance with applicable privacy laws, we have automatically honored your preference and disabled all non-essential cookies and tracking.
Only necessary cookies required for the website to function are enabled.
Opt-Out Request Honored
We have respected your privacy preference. Your opt-out request through cookie settings or Global Privacy Control signal has been honored.